glp-1 weight loss drugs news today drmcgowan was just featured in USA as an expert voice on the biggest drug story of the year. 📰 Eli Lilly's new drug retatrutide just posted the most significant World Health Organization issues first-ever

This review focuses on how GLP-1RAs impact lipid-related outcomes

Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated

Rhode Island's Medicaid agency proposes ending GLP-1 coverage for weight loss while keeping diabetes uses, citing soaring costs.

Additionally, we highlight the gaps for further studies in clinical applications of GLP-1 RAs in aging-related diseases

If youre considering pregnancy after using these medications, extra monitoring and support could make all the difference

Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss